摘要
目的探讨姜黄素逆转人结肠癌耐药细胞株HCT-116/5FU耐药的作用机制。方法姜黄素、5-FU诱导耐药细胞HCT-116/5FU凋亡,按对照组、5-FU组、姜黄素组及联合用药组分为四组,对照组予普通培养基;5-FU组予含5-FU 200μM培养基;姜黄素组予姜黄素20μM培养基;联合用药组予含5-FU 200μM和姜黄素20μM培养基。采用MTT法检测细胞增殖以明确最佳实验条件;AnnexinV-FITC试剂盒检测细胞凋亡率;Western blot检测亲本株及耐药细胞株内cleaved-Caspase3、IL-6、STAT3蛋白表达水平。结果姜黄素联合5-FU干预人结肠癌耐药细胞株HCT-116/5FU后细胞增殖受明显抑制;联合用药组HCT-116/5FU细胞凋亡率为(56.0±12.1)%,明显高于5-FU组(6.5±3.2)%和姜黄素组(19.9±7.2)%(P<0.05);耐药细胞株IL-6、STAT3蛋白表达明显高于亲本株;姜黄素降低耐药细胞株IL-6、STAT3的蛋白表达量,诱导cleaved-Casepase 3蛋白表达。结论姜黄素能逆转人结肠癌耐药细胞株HCT-116/5FU耐药,其机制可能与下调IL-6/STAT3有关。
Objective To explore the mechanism of curcumin in reversing drug resistance of human colon cancer cell line HCT-116/5FU.Methods Curcumin and 5-FU induced the apoptosis of HCT-116/5FU cells.Cells were divided into 4 groups,i.e.,control group,5-FU group,curcumin group and drug combination group.The control group was cultured in ordinary medium;the 5-FU group was treated with 200μm 5-FU;the curcumin group was treated with 20μM curcumin;the drug combination group was treated with 200μM 5-FU and 20μM curcumin.MTT method was used to detect cell proliferation in order to determine the best experimental conditions;annexin V-FITC kit was used to check apoptosis rate;Western blot was performed to test the expression levels of cleaved-caspase 3,IL-6,STAT3 protein in parental and drug-resistant cell lines.Results Curcumin combined with 5-FU significantly inhibited the proliferation of human colon cancer cell line HCT-116/5FU after treating.The apoptosis rate of HCT-116/5FU cells in the drug combination group was(56.0±12.1)%,significantly higher than that of 5-FU group(6.5±3.2)%and curcumin group(19.9±7.2)%(P<0.05).Expression of IL-6 and STAT3 protein in drug-resistant cells was significantly higher than that of parental cells.Curcumin reduced the expression of IL-6 and STAT3 protein in drug-resistant cells to induce cleaved casepase 3 protein expression.Conclusion Curcumin can reverse the drug-resistance of human colon cancer cell line HCT-116/5FU,and its mechanism may be related to down-regulation of IL-6/STAT3.
作者
徐露
张鑫杰
张闰哲
姚庆华
XU Lu;ZHANG Xinjie;ZHANG Runzhe;YAO Qinghua(Second Clinical College of Zhejiang Chinese Medical University,Hangzhou,Zhejiang province,310053,China;Department of Integrated Traditional Chinese and Western Medicine,Cancer Hospital of University of Chinese Academy of Sciences,Hangzhou,Zhejiang province,310022,China)
出处
《浙江中西医结合杂志》
2020年第6期454-457,I0002,共5页
Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
基金
国家自然科学基金项目(No.81673813)。
